- Factors associated with complete adherence to HIV combination antiretroviral therapyTimothy Juday
Bristol Myers Squibb, Plainsboro, NJ, USA
HIV Clin Trials 12:71-8. 2011..To assess factors associated with adherence, particularly pill burden, to combination antiretroviral therapy (cART) using multivariate models...
- Cost-effectiveness of entecavir versus adefovir for the treatment of chronic hepatitis B in patients with decompensated cirrhosis from a third-party US payer perspectiveNaoky Tsai
John A Burns School of Medicine, University of Hawaii, Honolulu, HI, USA
Clinicoecon Outcomes Res 4:227-35. 2012..Although entecavir has been shown to improve health outcomes in a cost-effective manner in mixed populations of CHB patients, the cost-effectiveness of entecavir has not been evaluated in CHB patients with decompensated cirrhosis...
- Adherence to chronic hepatitis B treatment guideline recommendations for laboratory monitoring of patients who are not receiving antiviral treatmentTimothy Juday
Research and Development, Bristol Myers Squibb Co, 777 Scudders Mill Road, Plainsboro, NJ 08536, USA
J Gen Intern Med 26:239-44. 2011..This study aimed to assess adherence to treatment guideline-recommended monitoring of CHB patients not receiving antiviral treatment and to identify predictors of laboratory monitoring and subsequent initiation of antiviral therapy...
- A retrospective study of HIV antiretroviral treatment persistence in a commercially insured population in the United StatesTimothy Juday
Bristol Myers Squibb Research and Development, Plainsboro, NJ, USA
AIDS Care 23:1154-62. 2011..39; p<0.001). HIV treatment persistence was longer with NNRTI-based regimens than PI-based regimens. The fixed-dose regimen of once-daily efavirenz/emtricitabine/tenofovir had the lowest risk of discontinuation...